Diazoxide

證據等級: L5

預測適應症: 10 個

Diazoxide: Insufficient Data for Repurposing Analysis

One-Sentence Summary

Diazoxide (DB01119) is a drug with no current New Zealand market authorization. The TxGNN pipeline did not return any predicted new indications for this candidate at this time, and key data fields including original indication and mechanism of action remain unavailable. No evidence-based recommendation can be issued until data gaps are resolved.

Quick Overview

Item	Content
Original Indication	Not available in current dataset
Predicted New Indication	None returned by TxGNN
TxGNN Prediction Score	N/A
Evidence Level	L5 — model prediction stage not yet reached
New Zealand Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why Analysis Cannot Proceed

Two blocking data gaps prevent standard repurposing analysis:

Mechanism of Action (MOA) is unavailable. Without understanding how diazoxide exerts its pharmacological effect, it is not possible to assess whether a predicted new indication shares mechanistic overlap with known therapeutic applications. MOA data can be retrieved from the DrugBank API using identifier DB01119.

Original indication data is absent. The regulatory dataset returned zero New Zealand product licenses, and no approved indication text is available to establish a baseline therapeutic context. Without this anchor, the "from X to Y" repurposing narrative cannot be constructed, and cross-indication plausibility cannot be evaluated.

In addition, no TxGNN predicted indications were returned in this evidence pack. This may reflect a pipeline issue, a model confidence threshold not being met, or missing upstream graph embedding data. The root cause should be investigated before proceeding.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN pipeline returned no predicted indications for diazoxide, and both the original indication and mechanism of action data are missing. There is no analytical basis on which to build a repurposing case at this time.

To proceed, the following is needed:

Resolve DG002 (High): Query the DrugBank API for DB01119 to retrieve mechanism of action, pharmacodynamics, and drug categories
Resolve DG001 (Blocking): Download and parse the package insert PDF from the TFDA website to obtain approved indications, warnings, and contraindications
Investigate TxGNN output gap: Confirm whether the empty predicted_indications array reflects a genuine model result (no confident predictions) or an upstream data pipeline failure
Supplement safety data: Once the package insert is retrieved, populate key warnings, contraindications, and drug interaction data before safety screening can proceed
Re-run evidence pack generation after all data gaps are resolved to enable a full L1–L5 evidence assessment
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.